生物活性 | |||
---|---|---|---|
描述 | Bumetanide is an inhibitor of Na(+)-K(+)-2Cl(-) co-transporter (NKCC) with an IC50 of 0.6 uM. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT03296813 | Heart Failure | Phase 3 | Recruiting | August 14, 2022 | - |
NCT00608491 | Heart Failure | Phase 3 | Completed | - | United States, Arizona ... 展开 >> Mayo Clinic Arizona Phoenix, Arizona, United States, 85054 United States, Georgia Morehouse School of Medicine Atlanta, Georgia, United States, 30310 United States, Minnesota Minnesota Heart Failure Network Minneapolis, Minnesota, United States, 55415 Mayo Clinic Rochester, Minnesota, United States, 55905 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27705 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 United States, Utah University of Utah Health Sciences Center Murray, Utah, United States, 84107 United States, Vermont University of Vermont - Fletcher Allen Health Care Burlington, Vermont, United States, 05401 Canada, Quebec Montreal Heart Institute Montreal, Quebec, Canada, H1T - 1C8 收起 << |
NCT00608491 | - | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.74mL 0.55mL 0.27mL |
13.72mL 2.74mL 1.37mL |
27.44mL 5.49mL 2.74mL |
参考文献 |
---|